Tome Biosciences, a genetic medicines startup in the biotechnology industry, is laying off 131 employees, which represents essentially its entire workforce of about 130 people. The layoffs, announced via a regulatory notice in late August 2024, are a result of severe funding challenges. The company, which launched publicly in December 2023 with $213 million in funding, has been unable to secure a new financing round amid a tough investment climate for preclinical gene-editing firms. This has forced Tome to scale back operations drastically while it explores strategic options.
